These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 18390906)
1. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. Ross HR; Napier I; Connor M J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906 [TBL] [Abstract][Full Text] [Related]
2. Modulation of Recombinant Human T-Type Calcium Channels by Δ Mirlohi S; Bladen C; Santiago M; Connor M Cannabis Cannabinoid Res; 2022 Feb; 7(1):34-45. PubMed ID: 33998881 [No Abstract] [Full Text] [Related]
3. A Critical Review of the Role of the Cannabinoid Compounds Δ Jones É; Vlachou S Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of recombinant Ca(v)3.1 (alpha(1G)) T-type calcium channels by the antipsychotic drug clozapine. Choi KH; Rhim H Eur J Pharmacol; 2010 Jan; 626(2-3):123-30. PubMed ID: 19782679 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Ross HR; Gilmore AJ; Connor M Br J Pharmacol; 2009 Mar; 156(5):740-50. PubMed ID: 19226289 [TBL] [Abstract][Full Text] [Related]
7. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
8. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Miller S; Daily L; Leishman E; Bradshaw H; Straiker A Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5904-5911. PubMed ID: 30550613 [TBL] [Abstract][Full Text] [Related]
9. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Pertwee RG Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291 [TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related]
11. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids. Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166 [TBL] [Abstract][Full Text] [Related]
12. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism. Xiong W; Koo BN; Morton R; Zhang L Neuroscience; 2011 Jun; 184():28-37. PubMed ID: 21477640 [TBL] [Abstract][Full Text] [Related]
13. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755 [TBL] [Abstract][Full Text] [Related]
14. Effects of Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys. Carey LM; Maguire DR; France CP Drug Alcohol Depend; 2023 Mar; 244():109787. PubMed ID: 36753805 [TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination. Linher-Melville K; Zhu YF; Sidhu J; Parzei N; Shahid A; Seesankar G; Ma D; Wang Z; Zacal N; Sharma M; Parihar V; Zacharias R; Singh G PLoS One; 2020; 15(6):e0234176. PubMed ID: 32497151 [TBL] [Abstract][Full Text] [Related]
18. Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Laaris N; Good CH; Lupica CR Neuropharmacology; 2010; 59(1-2):121-7. PubMed ID: 20417220 [TBL] [Abstract][Full Text] [Related]
19. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model. Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405 [TBL] [Abstract][Full Text] [Related]
20. The effect of Δ9-tetrahydrocannabinol on 5-HT3 receptors depends on the current density. Yang KH; Isaev D; Morales M; Petroianu G; Galadari S; Oz M Neuroscience; 2010 Nov; 171(1):40-9. PubMed ID: 20800662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]